What is PPD?
Founded in 1985, Pharmaceutical Product Development (PPD) operates as a prominent contract research organization (CRO). The company provides comprehensive services across the entire drug lifecycle, from initial discovery and development through to post-market management. PPD serves a diverse clientele, including pharmaceutical giants, emerging biotechnological firms, medical device manufacturers, academic institutions, and governmental organizations, facilitating their research and development initiatives.
How much funding has PPD raised?
PPD has raised a total of $2.2B across 2 funding rounds:
Other Financing Round
$550M
Stock Offering
$1.6B
Other Financing Round (2017): $550M with participation from GIC and Hellman & Friedman
Stock Issuance/Offering (2020): $1.6B, investors not publicly disclosed
Key Investors in PPD
GIC
GIC, a Singaporean sovereign wealth fund established in 1981, manages the nation's foreign reserves. They focus on securing Singapore's financial future through diverse investments in public and private markets.
Hellman & Friedman
Hellman & Friedman, founded in 1984, is a San Francisco-based private equity firm specializing in buyouts, restructurings, and various investment types across sectors like financial services, healthcare, and technology.
What's next for PPD?
The recent major strategic investment indicates PPD is poised for significant scaling and potentially further diversification of its service offerings. This infusion of capital is likely to accelerate its global expansion, enhance its technological capabilities in drug development, and strengthen its position as a leading CRO. The company may also pursue strategic acquisitions or partnerships to broaden its market reach and service portfolio, aiming to capitalize on the evolving landscape of pharmaceutical and biotechnology research.
See full PPD company page
